Anglikon, 29 September 2023: Vitruvia Medical AG achieves results as expected in the first half of 2023. The Board of Directors confirms the guidance for the full year.
Vitruvia Medical AG is on target in the first six months of 2023. The company generated consolidated revenues of approximately EUR 855,000.00 in the first half of 2023, with earnings before interest, taxes, depreciation and amortization of EUR -176,884.00.
Based on the results for the first half of 2023, which were as expected, the management confirms the outlook for the current full year. For this period, the Board of Directors expects consolidated revenues of approximately EUR 1.8 million. On a consolidated basis, Vitruvia Medical AG anticipates a further improvement in earnings compared to the previous year, which will, however, still be in negative territory.
About Vitruvia
Vitruvia Medical AG is a Swiss investment company focusing on the repair, production and trade of medical devices as well as surgical instruments.
Vitruvia thus combines innovative and sustainable solutions for medical-technical progress, customer benefit and economic success.
Contact:
Vitruvia Medical AG
Markus A. Bertschin
Board of Directors
T +41 44 915 33 78
bertschin@vitruvia-med.com